CLINICAL UROLOGY | TRANSLATIONAL SCIENCE | NURSING & … · 2019. 6. 24. · Clinical Urology 20-21...

Australian

Prostate Cancer

Research

Asia-Pacific Prostate Cancer Conference 2014

15th

Follow us on twitter #apcc14@AustProstate

31 AUGUST - 2 SEPTEMBER 2014MELBOURNE CONVENTION AND EXHIBITION CENTREMelbourne, Australia

CLINICAL UROLOGY | TRANSLATIONAL SCIENCE | NURSING & ALLIED HEALTH

www.prostatecancerconference.org.au

Conference Program

Principal Sponsor

Sponsors and Partners

We thank our Sponsors and Partners for their support.

Gold Sponsors

Silver Sponsors

Pa

ge 3

Breakfast Sponsors

Translational Science Clinical Urology

Welcome Reception and Poster Awards Sponsor

Lanyard and Name Badge Sponsor

da Vinci Masterclass Sponsors

Satellite Evening Session Sponsor

Welcome!

Welcome to the 15th Asia-Pacic Prostate Cancer Conference. We are proud to again bring the world's experts together and celebrate 15 years of industry education this year.

2014 brings with it a number of new educational opportunities for attendees, including the MRI Masterclass, which sold out swiftly. As always, the Conference will empower our health care industry to implement improved patient care practices and provide up to date information for patients to make informed choices.

Men's health will feature more broadly this year, with opinion leaders addressing the lag in specialist services for men. The program also includes specialised meetings for all practitioners involved in prostate cancer care delivery including: Urologists, RadiologistsRadiation Oncologists, Medical Oncologists, Researchers, Nurses, General Practitioners, Psycho-Oncologists, Physiotherapists and more.

We look forward to welcoming you in coming together as an industry for this international event in Melbourne. Thank you for participating and we hope you nd the 15th Asia-Pacic Prostate Cancer Conference informative and inspiring.

Prof Tony CostelloPresident,

15th Asia-Pacic Prostate Cancer Conference Executive Director, Australian Prostate Cancer Research

Pa

ge 4

Contents


15th

Welcome 4Host and Committees 6International Speakers 8-9National Speakers 10

ProgramSunday 31st August 11-12Monday 1st September 12-15Tuesday 2nd September 16-17Janssen Satellite Symposium 19

Posters Clinical Urology 20-21Nursing & Allied Health 22-23Translational Science 24

Clinical Urology Meeting 25Nursing & Allied Health 26-27Translational Science Program 28Masterclasses 29-31Social Program 32Registration Information 33Presentation Information 34Melbourne 34-35General Information 36Exhibition Information 37-38Exhibitor Proles 39-45


15th

Australian Prostate Cancer Research is a national research organisation that partners with leading institutions to develop, fund and deliver national research programs. We are committed and driven to discover the cause of prostate cancer, improve patient outcomes and educate people on all aspects of diagnosis, treatment and patient care, thereby empowering men and their families.www.prostatecancerresearch.org.au

Australian Prostate Cancer Research would like to thank the following individuals for their involvemen in the 15th Asia-Pacic t Prostate Cancer Conference.

Asia-Pacic Prostate Cancer Conference – Founder & ConvenorProf Anthony CostelloExecutive Director, Australian Prostate Cancer Research, Director of Urology, Royal Melbourne Hospital

Local Organising Committee

Program SecretaryDr Phil DundeeRoyal Melbourne Hospital, Western General Hospital, Epworth Prostate Centre

Clinical Urology Stream ConvenorA/Prof Declan MurphyUrologist and Director of Robotic Surgery, Peter MacCallum Cancer Centre, Epworth Prostate Centre

Translational Science ConvenorsDr David SandallChief Operating Ofcer, Epworth Prostate Centre,

Prof John MillsDirector of Research and Development, TissuPath Specialist Pathology

Nursing & Allied Health Stream ConvenorsMs Helen CroweProstate Cancer Nurse Practitioner, Research Nurse, Epworth Prostate Centre

Dr Addie WoottenClinical Psychologist, Department of Urology, The Royal Melbourne Hospital. Director of Clinical & Allied Health Research, Epworth Prostate Centre, eHealth Research Manager; Australian Prostate Cancer Research

Dr Jane CrowePrivate General Practitioner & Prostate Cancer Physician, Epworth Prostate Centre

Mr James GarlandCEO, Australian Prostate Cancer Research

Mrs Sally MarascoBusiness Development Manager, Australian Prostate Cancer Research, Conference Manager

We are also grateful for the support of the program stream sub committee members whom are acknowledged on the program stream page.

Pa

ge 6

Pa

ge 8

Dr Mitchell Benson

International Speakers

(USA)Urology faculty at Columbia University and former Chair of the Department of Urology

Prof Jelle Barentsz

(Netherlands)Radbound University Medical CentreDepartment of Radiology

Dr Peter Carroll

Mr Paul Cathcart

(USA)Faculty in the Department of Urology at UCSF

(UK)Senior Lecturer in Genito-urinary OncologyConsultant Urological SurgeonProstate Cancer Lead – St Bartholomew’s Hospital London

Dr Matthew Cooperberg

(USA)A/Prof, Depts of Urology & Epidemiology & Biostatics, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Centre

Dr John Davis

(Netherlands)Associate Professor of Urology and Director of the prostate cancer surgery program at MD Anderson Cancer Center

Mr Markus Graefen

Prof Larry Goldenberg

(USA)Martini-Clinic, Prostate Cancer Center at the University of Hamburg

(Canada)Professor and Head,Department of Urologic Sciences, University of British Columbia

Prof Roger Kirby

(UK)Consultant Urologist, Director of The Prostate Centre

Mr Thomas Lynch

(Ireland)Consultant Urological Surgeon at St. James’s Hospital and Trinity College, Dublin


15th

Dr Juanita Crook

(Canada)Kelowna General Hospital

Pa

ge 9

Dr Christian Nelson

International Speakers continued

(USA)

Psychological liaison to Memorial Sloan Kettering’s genitourinary and sexual medicine services

Dr Matthew Smith

(USA)Director of the Genitourinary Malignancies Program at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School

Prof Bertrand Tombal

Dr Henk van der Poel

(Belgium)Chairman of the Division of Urology, Cliniques Universitaires Saint-Luc, Brussels

(Netherlands)Department of Urology, Netherlands Cancer Institute

Pa

ge 1

0


15th

National Speakers

Dr Arun AzadBritish Columbia Cancer Agency

Dr Pat Bowden Director of Epworth Radiation Oncology

Dr Prue Cormie Edith Cowan University,Health and Wellness Institute

Prof Mark Frydenberg

Prof Daniel Galveo

Mr Jeremy Grummet

A/Prof Chris Hovens

Dr Joe Ischia

Chairman, Department of Urology, Monash Medical Centre; Chairman, Institute of Specialty Surgery, Epworth Healthcare

Edith Cowan University, Health and Wellness Institute

Australian Urology Associates

The University of Melbourne, Epworth Prostate Centre

Austin Health

A/Prof Nathan Lawrentschuk Department of Surgery, Austin Hospital; Peter MacCallum Cancer Centre

Prof Robert Newton Edith Cowan University, Health and Wellness Institute


15th

Dr Ryan Stafford

Ms Kay Talbot

Dr Ben Tran

Mr Mark Trevaskis

Dr Patricia Neumann The Pelvic Floor Clinic

Dr Max Rutherford The Royal Melbourne Hospital

Peter MacCallum Cancer Centre

The University of Queensland

Australian Urology Associates

The Royal Melbourne Hospital

Edith Cowan University,Health and Wellness Institute

A/Prof Scott WilliamsPeter MacCallum Cancer Centre

Dr Shomik SenguptaThe Austin Hospital

A/Prof Penelope Schofield

Ms Sarah Woollet Independent Researcher

Dr Addie WoottenAustralian Prostate Cancer Research

Pa

ge 1

1

0800 4th da Vinci Prostatectomy Masterclass

Room 219

See page 29 for full program details

Nursing & Allied Health

Continence

Plenary 3

Chairs: Shan Morrison and Adam Landau

0800 Welcome | Addie Wootten and Helen Crowe

0805 Qualitative experiences of patients with incontinence | Sarah Woollet

0830 Dynamics of the male pelvic floor | Ryan Stafford

0900 Teaching pelvic floor exercises to men before prostate surgery – what is best practice? | Trish Neumann

0930 The impact of incontinence on sexual intimacy | Panel discussion with Roger Kirby

1000-1030

MORNING TEA

1030-1230

4th da Vinci Prostatectomy Masterclass

Room 219


LDR Brachytherapy Masterclass

Room 218


Prostate MRI Imaging & Biopsy Masterclass

Room 220



Active Surveillance

Plenary 3

Chairs: Kay Talbot and Paul Cathcart

1030 Setting the scene, Active Surveillance versus Watchful Waiting and an overview of the current management protocols for Active Surveillance | Mark Frydenberg

1100 An overview of biopsy techniques and implications for the patient: Transperineal versus TRUS | Jeremy Grummet

1130 The personal and psychosocial experiences of Active Surveillance | Penelope Schofield

1200 Active Surveillance for Prostate Cancer – Potential Application of Exercise Medicine | Daniel Galveo

1230-1330

LUNCH


Room 219



Room 218



Room 220



Hormone Therapy

Plenary 3

Chairs: Addie Wootten and Robert Newton

1330 Androgen Deprivation Therapy, Setting the scene: A brief overview | Helen Crowe and Kay Talbot

1345 The physiological impact of Androgen Deprivation Therapy: Managing the side effects | Jane Crowe

1410 The cognitive impact of hormone therapy | Christian Nelson

1435 Improving mental wellbeing through exercise: a support group tailored for men with prostate cancer | Prue Cormie

Sunday 31st August 2014

Nursing & Allied Health Translational Science Clinical Urology

0745-0800

Combined Multidisciplinary Plenary

Plenary 3

Chair: Tony Costello, Roger Kirby, Larry Goldenberg

0745 Conference Opening & Welcome | Prof Tony Costello

0800 Ministerial Address | Hon. Peter Dutton MP

0815 Men's Health: The Final Piece of the Puzzle of Family Health | Larry Goldenberg

0835 The trouble with men | Roger Kirby

0840 Life without PSA testing – future predictions if the USPSTF had their way | Matthew Cooperberg

0855 Characterisation of a high volume center for radical prostatectomy – perspectives beyond surgical expertise | Markus Graefen

0910 State-of-the-Art mp-MRI: clinical role and PI-RADS reporting | Jelle Barentsz

0925 The timing of androgen deprivation therapy – new perspectives in 2014 | Bertrand Tombal

0940 Optimal timing and sequencing of new androgen pathway inhibitors in castration-resistant prostate cancer | Matthew Smith

0955 Questions

0958 Prostate Cancer World Congress 2015 Announcement

1000-1030

MORNING TEA

Pa

ge 1

2

1500-1530

AFTERNOON TEA

1530-1700


Room 219



Room 218



Room 220



Advanced prostate cancer

Plenary 3

Chairs: Helen Crowe and Phil Dundee

1530 Reflections upon the provision of psychological support to men with Advanced Prostate Cancer | Max Rutherford

1550 New radiation therapy techniques for advanced prostate cancer | Pat Bowden

1610 New systemic treatments and agents for advanced prostate cancer | Ben Tran

1630 Panel discussion – the challenges of managing and supporting the complex advanced prostate cancer patient | Panel

1650 Discussion of resources available and how to access them

1655 Meeting close Addie Wootten & Helen Crowe

1700-1900

Poster and Welcome Reception

Exhibition Area

Sunday 31st August 2014

Monday 1st September 2014


Pa

ge 1

3

1030-1230

Oligometastatic disease

Plenary 3

Chair: Declan Murphy, Joseph Bucci

1030 Introduction | Declan Murphy

1035 The molecular imaging of oligometastatic disease | Scott Williams

1050 Nodal Imaging revisited | Jelle Barentsz

1105 The role of radical prostatecomy in metastasized prostate cancer | Markus Graefen

1120 Stereotactic radiotherapy for oligometastatic disease | Pat Bowden

1135 The choice of systemic therapies in low-volume metastatic disease | Ben Tran

1150 2nd Patrick C Walsh Lecture – Introduction | Tony Costello

1200 2nd Patrick C Walsh Lecture: Refined prostate cancer risk assessment leads to refined treatment | Peter Carroll

Therapies

Room 218

Chair: Prof Colleen Nelson

1030 Repositioning "Old" Drugs for New Causes: Identifying New Treatments for Metastatic Prostate Cancer | Esha Shah

1045 BDX1: A natural small molecule activator of the amino acid stress response pathway in prostate cancer cells | Michelle Liberio

1100 The Ascidian natural product EB activates DNA damage response pathways through inhibition of topoisomerase II in LNCaP cells | Michelle Liberio

1115 Co-targeting H2 relaxin and androgen signalling in prostate cancer | Gregor Tevz

1130 Mechanism of action studies in prostate cancer cells on new compounds isolated from an Australian endemic rainforest tree | Claire Levrier

1145 Targeting neuropilin-1 to inhibit prostate cancer metastasis and therapy resistance | Brett Hollier

1205 Circulating microRNAs associated with docetaxel chemotherapy outcome of prostate cancer | Hui-Ming Lin

Current Nursing and Allied Health Research Trends

Room 220

Chairs: Robert Newton and Christian Nelson

1030 Effects of a clinician’s referral and physical activity program for men who have completed treatment for prostate cancer: A multicentre cluster randomized controlled trial [ENGAGE] | Patricia Livingston

1040 The efficacy of a clinician referred exercise training program on markers of cardiometabolic risk for prostate cancer survivors | Patrick Owen

1050 Preliminary results of My Road Ahead: An online psychological intervention for men with prostate cancer | Addie Wootten

1100 Engaging Men with Prostate Cancer: The development of a tumour specific Living with Cancer Education Program | David Gray

1110 Self-esteem, body image, sexual and urinary function of gay and straight prostate cancer survivors: Is there really a difference? | Christopher Thomas

1120 Reduction of fatigue in men on ADT for prostate cancer: effect of varying exercise modes | Dennis Taaffe

1130 Are current definitions of depression inadequate for prostate cancer patients? | Vicki Bitsika

1140 Pelvic Floor muscle contraction with verbal instruction- do men get it? | Patricia Neumann

1150 Psychological Distress and Advanced Prostate Cancer | Leah Zajdlewicz

1200 The efficacy of a clinician referred supervised exercise training program on fitness, body composition and physiological outcomes for prostate cancer survivors | Steve Fraser

1210 Maximal exercise testing of men with prostate cancer being treated with ADT | Bradley Wall

1220 Discussion and presentation of Best Oral Paper prize



Pa

ge 1

4

1230-1330

LUNCH

1330-1500

Patterns of Care, Risk Stratication and Active Surveillance

Plenary 3

Chair: Nathan Lawrentschuk, Mark Frydenberg

1330 Patterns of care for men with a prostate cancer diagnosis in Victoria | Jeremy Millar

1345 How we set up a National Prostate Cancer Audit – the English experience | Paul Cathcart

1400 Point-counterpoint: we must do transperineal prostate biopsy | Jeremy Grummet

1410 Point-counterpoint: TRUS prostate biopsy is fine | Shomik Sengupta

1420 Active surveillance – has the pendulum swung too far? | Nathan Lawrentschuk

1425 Is active surveillance for low risk prostate cancer really safe? | Mitchell Benson

1440 Active surveillance for early-stage prostate cancer – who, how and for how long | Peter Carroll

1455 Questions & Answers | Panel

Metastasis and Progression

Room 218

Chair: Prof Pamela Russell

1330 Evading immune surveillance as a mechanism of prostate cancer metastasis to bone | Nikola Baschuk

1345 Increased expression of the ETS1 transcription factor promotes epithelial-to-mesenchymal transition (EMT) in prostate cancer cells | Marc Thomas

1400 Tie-2 regulates stemness and metastasis of prostate cancer cells | Patrick Ling

1415 YB-1, a driver of prostate cancer progression | Anja Rockstroh

1435 MicroRNA-194 promotes migration and invasion of prostate cancer cells by regulating epithelial-mesenchymal transition | Rajdeep Das

1500-1530

AFTERNOON TEA



Pa

ge 1

5

1530 Radical Prostatectomy State of the Art

Plenary 3

Chair: Peter Swindle, Tom Shannon

1530 Personal perspective on open and robotic prostatectomy | Peter Carroll

1545 Improving functional outcome after radical prostectomy | Markus Graefen

1600 Extended PLND-Technique, Patient Selection, and Results | John Davis

1615 Optimising outcomes of RARP through modular and Fellowship training – ERUS initiatives | Henk Van der poel

1630 Salvage radical prostatectomy post-focal and whole-gland HIFU | Paul Cathcart

1645 Robotic Surgery Simulation: The opportunities and the challenges | Jeff Berkley

1700 Discussion | Panel

Biomarkers and Diagnostics

Room 218

Chair: Prof Judith Clements

1530 Circulating microRNAs as biomarkers and regulators of prostate cancer | Luke Selth

1545 A Novel Protein Biosensor for Early Prostate Cancer Diagnosis | Masuda Nabi

1600 Methylated glutathione s-transferase 1 (mGSTP1) as a potential plasma epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer (CRPC). | Kate Mahon

1615 Overexpression of ACSM1,CACNA1D and LMNB1, three novel biomarker candidates in prostate cancer | Saeid Alinezhad

1635 Loss of stromal androgen receptor in prostate cancer results in poor patient outcome by altering the composition of the extracellular matrix, leading to enhanced cancer cell migration and invasion | Damien Leech

Latest exercise prescription for men with prostate cancer: Interactive Workshop

Room 220

1530 Interactive workshop exploring the most up to date exercise prescription for men with prostate cancer

Prof Rob NewtonProf Daniel Galvao Dr Prue Cormie Mark Trevaskis

Pre-registration required

Registrants are invited to wear exercise clothing

1730-1830

Room 218

Chair: Lisa Horvath

Changes in the clinical paradigm of advanced prostate cancer in light of emerging systemic agents |

Peter Carroll

1900-2330

APCC 2014 Conference Dinner

Mural Hall



Pa

ge 1

6

Tuesday 2nd September 2014

0645 BREAKFAST SESSION

Room 219

Chair: Nathan Lawrentschuk

Bayer-sponsored breakfast session

Sequencing of therapies in metastatic prostate cancer: how and when | Matthew Smith

BREAKFAST SESSION

Room 220

Sanofi-sponsored breakfast session

The Genomic Era of Translational Medicine | Prof Vanessa M. Hayes

0755-1000

Combined Multidisciplinary Plenary

Plenary 3

Chair: Scott Williams, John Yaxley

0755 Welcome | Chair

0800 Screening for prostate cancer: Do the U.S. Preventive Services Task Force (USPSTF) recommendations make sense? | Mitchell Benson

0815 Genomic Classifiers for Prostate Cancer – How to Evaluate Clinical Validity vs Utility | John Davis

0830 Androgen receptor DNA binding profiling in prostate cancer | Henk Van der Poel

0845 MSH2, prostate cancer and Lynch syndrome: a mismatch made in Hell? | Chris Hovens

0900 Minimising the harms of androgen deprivation therapy | Bertrand Tombal

0915 Standardisation of assay methods limits variability of total PSA measurements | Thomas Lynch

0930 Low dose rate prostate brachytherapy as a boost or monotherapy: long term results that are hard to beat | Juanita Crook


0955 Message from Principal Sponsor AstraZeneca | Christopher Goon

1000-1030

MORNING TEA

1030-1230

CRPC Changing Paradigms

Plenary 3

Chair: Daniel Moon, Shahneen Sandhu

1030 Prevention and treatment of bone metastases in prostate cancer | Matthew Smith

1045 Timing and modalities of AR targeted agents during early CRPC | Bertrand Tombal

1100 The Urologist's role in the treatment of castrate resistant prostate | Mitchell Benson

1115 Patient selection for abiraterone – who is most likely to respond? | Arun Azad

1130 How docetaxel fits in the changing landscape | Ben Tran

1145 CRPC case discussion | Panel

1220 Life in the Fast Lane – John Fitzpatrick remembered | Roger Kirby

Therapeutic Targets

Room 218

Chair: A/Prof Lisa Horvath

1030 Monoterpene glycoside, ESK246, targets LAT3-mediated amino acid transport and cell growth in prostate cancer | Qian Wang

1045 Investigating the PI3K pathway in prostate cancer | Helen Pearson

1100 PTRF decreases prostate cancer angiogenesis potential | Zeyad Nassar

1115 Elucidating the molecular action of synthetic heat shock protein 90 inhibitors in prostate cancer | Heather Armstrong

1130 Inhibition of fatty acid synthase suppresses androgen signaling in LNCaP cells | Martin Sadowski

1145 Androgen receptor influences the proliferation of prostate cancer cells through exosomes | Carolina Soekmadji

1205 Feasting in a time of famine – mechanisms of castration resistance | Niall Corcoran


1230-1330

LUNCH

1330-1500

High-risk non-met

Plenary 3

Chair: Henry Woo, James McKean

1330 Management of high-risk, non-metastatic prostate cancer – are all options truly equivalent? | Peter Carroll

1350 The evolution of HDR prostate brachytherapy: has it come of age? | Juanita Crook

1405 PLND & Fluorescence guided sentinel node imaging for prostate cancer | Henk van der Poel

1420 Management of High Risk Prostate Cancer – MD Anderson approach | John Davis

1435 Is intraoperative Choline Positron Emission Tomography (PET) during robotic prostatectomy ready for PRIME time use: introducing the PRIME study | Paul Cathcart

1450 Vancouver approach to very high-risk prostate cancer | Joe Ischia

Prostate Cancer Genetics and Epigenetics

Room 218

Chair: Dr Niall Corcoran

1330 Intra-metastatic heterogeneity and treatment induced remodelling of subclonal architecture of lethal prostate cancer | Chris Hovens

1345 Functional analysis of the KLK3 variants, found to be associated with prostate cancer risk | Srilakshmi Srinivasan

1400 Association and functional analysis of miRSNP in prostate cancer – results from the large collaborative oncological genetics studies (COGS) | Jyotsna Batra

1415 Identification of candidate functional short tandem repeats for analysis in large case-control prostate cancer risk studies. | John Lai

1430 Macrophage inhibitory cytokine-1 (MIC-1/GDF15) gene deletion is associated with increased tumor growth in TRAMP prostate cancer-prone mice. | Yasmin Husaini

1445 Genomic analysis of circulating tumor DNA in plasma of metastatic castration-resistant prostate cancer patients treated with abiraterone acetate and enzalutamide | Arun Azad

1505 Significance of ethnic-based disparities in prostate cancer risk and outcomes | Vanessa Hayes

1500-1530

AFTERNOON TEA

1530-1700

Looking after men post-treatment

Plenary 3

Chair: David Winkle, Phil Dundee

1530 Prostate Cancer Survivorship – improving outcomes | Matthew Smith

1545 The role of exercise in improving outcomes and quality of life for men with metastatic prostate cancer | Rob Newton

1600 The impact of surgery on erectile function and how to help men recover function | Chris Nelson

1615 Testosterone Replacement Therapy: How safe is it? | Larry Goldenberg

1630 PROSTMATE – an online platform enabling survivorship care | Addie Wootten


1655 Meeting close | Tony Costello

1700 CONFERENCE CONCLUDES

Tuesday 2nd September 2014

Pa

ge 1

7


Pa

ge 1

8

Janssen Satellite Symposium

Changes in the clinical paradigm of advanced prostate cancer in light of emerging systemic agents

Date: Monday 1st September 2014

Time: 17:30 – 18:30 (refreshments from 17:15)

Location: Melbourne Convention Centre

Chairs: Dr Lisa Horvath

Speakers: Dr Peter Carroll

The real world management of patients with prostate cancer

Dr Peter CarrollDr. Peter Carroll received his undergraduate training at the University of California, Berkeley. After graduating with honors from Georgetown University School of Medicine, he came to UCSF for his general surgery training and urology residency. He completed a fellowship in Urologic Oncology at Memorial-Sloan Kettering Cancer Center before returning to join the faculty in the Department of Urology at UCSF.

Pa

ge 1

9

7 Inguinal Hernia Rates After Robot-Assisted Radical Prostatectomy: Our 5-year Experience at Singapore General Hospital

Weber Lau

18 The oncological outcomes of robotic assisted radical prostatectomy in an unscreened multi-racial Asian population

Alvin Wei Xiang Low

23 Emerging Trends in the Terminology of Prostate Cancer Treatment Jonathon Lo

32 Transrectal Ultrasound-Guided Prostate Biopsy Sepsis: A Worldwide Literature Review On Rates, Risk Factors And Prophylaxis

Elliot Anderson

33 The cost of management for patients with metastatic prostate cancer in New Zealand Chunhuan Lao

40 Oncological Outcomes of Robotic Prostatectomy in the Victorian Public Sector Niranjan Sathianathen

42 Prostate Cancer Registry (PCR) quality of life outcomes following prostate cancer treatment

Jeremy Millar

43 Satisfaction and Regret following RALP may not always reflect continence and erectile function

Milan Thomas

51 Transitional experience from pure laparoscopic to robotic-assisted radical prostatectomy: An Australian single surgeon series

Daniel Moon

54 Influence of variation in use of radical therapy on risk-adjusted prostate cancer mortality in England and the US

Paul Cathcart

58 Comparison of Short Term Oncological and Functional Outcomes between Open and Robotic-Assisted Radical Prostatectomy for Localized Prostate Cancer in the Victorian Prostate Cancer Registry

Wee Loon Ong

59 Extended thromboembolism prophylaxis post open radical prostatectomy is safe and effective

Daniel Chen

65 Incontinence after prostatectomy is related to urethral mechanics observed with transperineal ultrasound imaging

Ryan Stafford

69 Proton beam therapy websites: Characteristics and claims Sarah O'Neill

70 Practice patterns and perioperative outcomes of radical prostatectomy in Victoria: A comparison of open, laparoscopic and robotic prostatectomy in 5130 patients over 3 years

Niranjan Sathianathan

72 A health economic analysis of robotic surgery in the Australian public health system Niranjan Sathianathan

73 No difference on overall survival rate between patients with prostate cancer who underwent surgical hormonal therapy and medical hormonal therapy

Untung Tranggono

77 Pathways of care for metastatic prostate cancer patients in the Midland Cancer Network, New Zealand

Ross Lawrenson

82 Prevention of symptomatic skeletal events in patients with genitourinary tumours and bone metastases treated with denosumab or zoledronic acid

Kenneth Pittman

84 Treatment for localized prostate cancer in New Zealand men in light of clinical guidelines

Zuzana Obertova

85 The burden of skeletal-related events (SREs) on pain outcomes in patients with castration-resistant prostate cancer (CRPC) and bone metastases

Matthew Smith

PostersClinical Urology

Pa

ge 2

0


15th

Posters continued

87 Prostate Volume Estimation in Prostate Cancer: Are Urologists or Radiologists More Accurate?

Steffi Yuen

88 Transrectal ultrasound-guided biopsy with anterior needles improves detection and localisation of prostate cancer in men undergoing active surveillance

Arveen Kalapara

91 Does sparing the neurovascular bundle affect urinary continence outcomes in men undergoing radical prostatectomy? A Systematic Review

Fairleigh Reeves

94 The utilisation of Active Surveillance in a Victorian cohort of men, according to PRIAS and other contemporary Active Surveillance protocols

Mahesha Weerakoon

107 Current use of Active Surveillance in Victoria, Australia: a patterns of care analysis from the Prostate Cancer Registry

Mahesha Weerakoon

108 Clinical use of a novel technique for ablation of prostate cancer, irreversible electroporation (IRE), and characterisation of the resulting prostate pathology

Jeremy Millar

110 The APCCR: beginning a global journey towards international benchmarking of prostate cancer outcomes

Sue Evans

113 Validation of the relationship between urethral motion measured with transurethral ultrasound imaging and activation of the striated muscle complexes of the male pelvic floor

Paul Hodges

118 Stereotactic body radiotherapy for oligometastatic prostate cancer: Retrospective series from a single Australian centre

Fairleigh Reeves

128 Biological imaging for focal brachytherapy for prostate cancer Scott Williams

131 Surgical outcomes of patients who fail active surveillance for localised prostate cancer in an Australian population

Arveen Kalapara

139 Prostate cancer in the elderly in Morocco: a retrospective review Hinde Hami

141 Prostate cancer in Niger: first results from a population-based cancer registry Hinde Hami

143 Results of surgical treatment of patients with clinically insignificant prostate cancer classified according Epstein criteria

Kirill Nyushko

144 Outcome prognostic factors in prostate cancer patients after surgical treatment Kirill Nyushko

158 Practice patterns of urologists in managing Korean males 40 years old or younger with high serum PSA levels

Dae-Seon Yoo

160 An initial Melbourne experience of multiparametric MRI for the diagnosis of prostate cancer

Sarah O’Neil

161 Does transperineal biopsy cause erectile dysfunction? Jeremy Grummet

162 Radical prostatectomy without prostate biopsy in PIRADS 5 lesion on 3T multi-parametric MRI of the prostate gland: 2 Case Reports

Andrew Keller

167 Zero sepsis in 452 consecutive transperineal biopsies: an update on the VTBC database

Jeremy Grummet

172 Evaluation of models predicting insignificant prostate cancer to select men for active surveillance of prostate cancer

Lih-Ming Wong

173 A comparison of two novel methods of analgesia for transrectal ultrasonography (TRUS)-guided prostate biopsy – Penthrox alone versus Penthrox plus periprostatic infiltration of local analgesia

Sean Huang

Clinical Urology

Pa

ge 2

1

10 Working with Grieving Adults: The Relevance of Attachment to Coping Styles John Toussaint

17 Trajectory of pain following open and minimally invasive radical prostatectomy for localised prostate cancer: An Australian multi-site, comparative study

Damien Khaw

19 Baseline characteristics of the participants in a telephone-delivered mindfulness intervention for men with advanced prostate cancer

Robert McDowall

20 Preliminary results of My Road Ahead: An online psychological intervention for men with prostate cancer

Addie Wootten

22 Effects of a clinician’s referral and physical activity program for men who have completed treatment for prostate cancer: A multicentre cluster randomized controlled trial [ENGAGE]

Patricia Livingston

24 Evaluation of the Outreach Clinics of the Prostate Cancer Specialist Nurse in Tamworth, NSW

Sharon Slack

31 PROSPECT: Understanding how multiple factors interact to predict depression in prostate cancer patients and their partners during the first year after diagnosis

Chris Sharpley

34 Are current definitions of depression inadequate for prostate cancer patients? Vicki Bitsika

36 Engaging Men with Prostate Cancer: The development of a tumour specific Living with Cancer Education Program

David Gray

38 Rethinking the DRE: Introducing novel non-invasive tests of pelvic floor muscle function in humans

Jo Milios

45 Self esteem, body image, sexual and urinary function of gay and straight prostate cancer survivors: Is there really a difference?

Christopher Thomas

46 Designing New Health Services for Advanced Prostate Cancer Patients: Challenges and Opportunities

Amol Wagholikar

47 The prevalence of depressive symptoms among patients undergoing low and high dose-rate brachytherapy for prostate cancer

David Christie

63 Reduced unmet supportive care needs after implementation of a prostate cancer specialist nursing service

Julie Sykes

64 Improving Patient Outcomes In Robotic Prostatectomy Patients Using A Nurse-Led Clinic

Emma Birch

66 Reduction of fatigue in men on ADT for prostate cancer: effect of varying exercise modes

Dennis Taaffe

78 Prostate cancer: Impact on quality of life for a cohort of New Zealand men Charis Brown

81 Building systematic access to psychological services for men with prostate cancer Tessa Jones

98 Psychological Distress and Advanced Prostate Cancer Leah Zajdlewicz

111 Maximal exercise testing of men with prostate cancer being treated with ADT Robert Newton

114 Establishment and evaluation of a multidisciplinary complex prostate cancer clinic Helen Crowe

Posters continued


Pa

ge 2

2


15th

Nursing & Allied Health120 The efficacy of a clinician referred exercise training program on markers of

cardiometabolic risk for prostate cancer survivorsPatrick Owen

130 Engaging Men with Prostate Cancer: The evaluation of a tumour specific. Living with Cancer Education Program

David Gray

150 Pre-operative Pelvic Floor Muscle Training: a Review Melissa Martin

152 Using web-enabled technology to support men with prostate cancer Addie Wootten

156 The efficacy of a clinician referred supervised exercise training program on fitness, body composition and physiological outcomes for prostate cancer survivors

Steve Fraser

163 Validation of a Nurse Led Robotic Prostatectomy Patient Pathway Emma Birch

164 Pelvic Floor muscle contraction with verbal instruction- do men get it? Patricia Neumann

174 Development and testing the acceptability of Rekindle, a web-based psychosexual resource for all cancer survivors and their partners

Zac Seidler

175 Qualitative experiences of patients with incontinence Sarah Woollet

Pa

ge 2

3

Posters continued

Pa

ge 2

4


15th

Posters continued

6 PTRF decreases prostate cancer angiogenesis potential Zeyad Nassar

11 Repositioning "Old" Drugs for New Causes: Identifying New Treatments for Metastatic Prostate Cancer

Esha Shah

13 Overexpression of ACSM1,CACNA1D and LMNB1, three novel biomarker candidates in prostate cancer

Saied Alinezhad

29 Circulating microRNAs associated with docetaxel chemotherapy outcome of prostate cancer

Hui-Ming Lin

30 Characterisation of ADAMTS-15: a potential tumour suppressor gene in Prostate cancer

Marley Binder

44 Disrupting caveolae promotes malignant behaviour in normal prostate cells Jin Yih Low

48 Monoterpene glycoside, ESK246, targets LAT3-mediated amino acid transport and cell growth in prostate cancer

Qian Wang

60 3D Bone Marrow Metastatic Prostate Cancer Niche Mimic Eman Mosaad

80 Relative cytotoxic potencies of alpha1-adrenoceptor antagonists on PC3 and LNCap prostate cancer cells

Amanda Forbes

99 Challenges and Opportunities in Establishing Biobanking from a Body Donor Program Allison Eckert

112 YB-1, a driver of prostate cancer progression Anja Rockstroh

115 BDX1: A natural small molecule activator of the amino acid stress response pathway in prostate cancer cells

Michelle Liberio

116 Androgen receptor influences the proliferation of prostate cancer cells through exosomes

Carolina Soekmadji

117 The ascidian natural product EB activates DNA damage response pathways through inhibition of topoisomerase II in LNCaP cells

Michelle Liberio

123 Mechanism of action studies in prostate cancer cells on new compounds isolated from an Australian endemic rainforest tree

Claire Levrier

124 Targeting neuropilin-1 to inhibit prostate cancer metastasis and therapy resistance Brett Hollier

127 Functional analysis of the KLK3 variants, found to be associated with prostate cancer risk

Srilakshmi Srinivasan

129 Association and functional analysis of miRSNP in prostate cancer - Result from the large collaborative oncological genetics studies (COGS)

Jyotsna Batra

132 Inhibition of fatty acid synthase suppresses androgen signalling in LNCaP cells Martin Sadowski

133 Defining the effect of metformin treatment in androgen deprived prostate cancer cells Jennifer Gunter

135 Androgen deprivation increases migration and invasion in prostate cancer cells and is increased by insulin

Phoebe Sarkar

137 Clinical Studies at the Australian Prostate Cancer Research Centre Queensland Maggie Fung

168 Australian Prostate Cancer BioResource, 2014 Trina Yeadon

Translational Science

Clinical Urology Meeting Following on the huge success of the Prostate Cancer World Congress in 2013, the Clinical Urology Stream at the 2014 Asia-Pacic Prostate Cancer Conference promises to raise the bar further again. The Melbourne Consensus Statement on the Early Detection of Prostate Cancer attracted worldwide attention upon its release at the 2013 meeting subsequent peer-review publication in the BJUI recently. This year, we again plan to leverage off the presence of so many world-leading prostate cancer experts to answer some of the key questions challenging us in clinical practice today. Our International Faculty contains a multidisciplinary mix of experts from the world of urology, medical oncology, radiation oncology, translational science, nursing and allied health, and will address some of the most pressing areas in prostate cancer today including:

Ÿ Diagnosis, staging & risk stratication

Ÿ Advances in MRI and other imaging

Ÿ Active surveillance

Ÿ Radical prostatectomy - improving outcomes

Ÿ Castrate resistant prostate cancer - the changing paradigm

Ÿ Advances in radiation oncology

In addition to the keynote addresses in the main plenary, we will present breakfast sessions, satellite sessions, specialist workshops and the 4th da Vinci Prostatectomy Masterclass.

We look forward to presenting another outstanding Clinical Urology Program at APCC 2014 and we thank you for your support.

Co ConvenorProfessor Tony Costello President, 15th Asia-Pacic Prostate Cancer Conference

Co ConvenorAssociate Professor Declan Murphy Convenor, Clinical Urology

Thank you to the support of our sub Committee Members

The Asia-Pacic Prostate Cancer Conference program has been reviewed by the Genitourinary Oncology Special Advisory Group (SAG) of the Urological Society of Australia and New Zealand. The following CPD pints have been conrmed:

Monday 1 September: 7 hours

Tuesday 2 September: 7 hours

Additional Breakfast Session Tuesday 2 September: 1 hour

Total CPD points for the full meeting: 14 points

Total CPD points for the full meeting including breakfast session Tuesday 2 September: 15 points

da Vinci Masterclass Sunday 31 August: 7 hours

LDR Brachy Masterclass Sunday 31 August: 5 hours

Prostate MRI Imaging & Biopsy Masterclass Sunday 31 August: 5 hours

in Category 4: Maintenance of Clinical Knowledge and Skills

Clinical Urology BreakfastTuesday 2 September 20140645 – 0745Sequencing of therapies in metastatic prostate cancer: how and whenDr Matthew Smith

Sponsored by Bayer

Dr Ben TranRoyal Melbourne Hospital, Melbourne

A/Prof Scott WilliamsPeter McCallum Cancer Centre, Melbourne

Pa

ge 2

5

Pa

ge 2

6


The Nursing and Allied Health stream showcases the most relevant information and education across the disciplines of nursing, psycho-oncology, continence practitioners and exercise physiology. This year these disciplines will join together to offer a comprehensive multidisciplinary approach to prostate cancer care in a full day program. The Nursing & Allied Health program will highlight how the professional expertise of these disciplines using a multi-disciplinary approach can enhance existing prostate cancer management and provide the best care for patients and their partners and families.

Sunday 31st August will provide a comprehensive

multidisciplinary series of sessions focussed on the care of men with prostate cancer across all stages of the disease. The opening session will focus on continence management, the second session will provide a multidisciplinary overview of active surveillance, the third session will explore the challenges of hormonal therapy and the nal session of the day will provide an insight into the complexities of advanced and metastatic prostate cancer.

Monday 1st September will showcase the best research

submitted for presentation in the nursing and allied health stream with a full session dedicated to original research presentations. Posters of submitted abstracts will also be on display for the entire conference period so please make sure you explore the fantastic work being conducted. On Monday afternoon an interactive exercise workshop will be presented by leading exercise physiology researchers from Edith Cowan University. This session will provide a hands-on experience of the latest evidence in exercise prescription for men with prostate cancer.

Highlights of the program include our international guest

speaker, Dr Christian Nelson, Clinical Psychologist from Memorial Sloan Kettering Cancer Centre in New York; and the interactive exercise workshop led by the expert exercise physiologists Prof Robert Newton, Dr Prue Cormie, Prof Daniel Galvao and Mark Trevaskis.

Co ConvenorMs Helen CroweUrology Nurse Practitioner, Research Nurse, Epworth Prostate Centre

Helen has been working in urology for over 20 years, and was instrumental in establishing urology nursing professional organisations in Australia. She is employed in a private urology practice, devoted to prostate cancer, as a Nurse Practitioner and at Epworth Prostate Centre as a research nurse. She has presented nationally and internationally, published and won awards for her work on the nursing management of men with prostate cancer.

Co ConvenorDr Addie Wootten Clinical Psychologist, Department of Urology, The Royal Melbourne Hospital. Director of Clinical & Allied Health Research, Epworth Prostate Centre, eHealth Research Manager, Australian Prostate Cancer Research

Dr Addie Wootten is a clinical psychologist who specialises in the area of prostate cancer. Dr Wootten is the eHealth research manager at Australian Prostate Cancer Research; the director of clinical and allied health research at the Epworth Prostate Centre and also works in the department of urology at The Royal Melbourne Hospital.

Pa

ge 2

7


Dr Jane CrowePrivate General Practitioner & Prostate Cancer Physician, Epworth Prostate Centre

Jane has worked over 20 years in General Practice in the Eastern suburbs of Melbourne. In 2011 Jane started work as a Prostate Cancer Physician, part time, at the Australian Prostate Cancer Research Centre, (Epworth) where she sees men with Advanced Prostate Cancer and manages and monitors the effects of hormone therapy and provides chronic disease management. Jane is also involved with Prostate Cancer Research, with a particular interest in Prostate cancer management in primary care.

Thank you to the support of our Sub Committee Members

Latest exercise prescription for men with prostate cancerDate: Monday 1 SeptemberTime: 15:30 – 17:00Location: Melbourne Convention Centre

Learn from the leaders in exercise interventions for men with prostate cancer. Prof Rob Newton, Prof Daniel Galveo, Dr Prue Cormie and Mark Trevaskis from Edith Cowan University will lead this interactive workshop that will fully equip you with the knowledge needed to advise your prostate cancer patients about the benets of exercise.

The ESSA Professional Development Committee certies that this Professional Development offering meets the criteria for 2 Continuing Professional Development (CPD) Points.

Ms Shan MorrisonWomen's and Men's Health Physiotherapy

Shan is a fellow of the Australian College of Physiotherapists and has post graduate qualications in Continence and Pelvic Floor Rehabilitation. She has over 20 years of experience and is the Director of Women's and Men's Health Physiotherapy, a Victorian private practice which specialises in managing female and male pelvic oor disorders. She has a particular interest in the prevention and management of incontinence pre and post prostatectomv.

Ms Kay TalbotPractice Manager/RN Australian Urology Associates

Kay is Practice Manager at Australian Urology Associates and has been involved in Urological nursing for many years. She has special interests in prosthetics in urology & nursing education. She was a founding member of the Victorian Urological Nurses Society, and the Australia and New Zealand Urological Nurses Society. Kay has been an invited speaker at numerous state and national education meetings, has several publications, and has received a number of awards associated with her interests in urological nursing care.

Nursing and Midwifery Board of AustraliaContinual Professional Development Registration Standard

One hour of active learning will equal one hour of CPD. It is the nurse or midwife's responsibility to calculate how many hours of active learning have taken place. If CPD activities are relevant to both nursing and midwifery professions, those activities may be counted in each portfolio of professional development.

Full attendance at this APCC 2014 offers 10.5 hours of nursing education.

Prof Robert NewtonEdith Cowan University

Professor Rob Newton is Foundation Professor in Exercise and Sports Science at Edith Cowen University Health and Wellness Institute, Perth, Western Australia. Current clinical and research directions include: exercise medicine for reducing decline in strength, body composition and functional ability in cancer patients; ADT toxicities; management of lymphedema.

Pa

ge 2

8

Translational Science Program

New TherapiesFrom “old” drugs through to newly isolated natural products, this session will explore novel targeted therapies for prostate cancer, biomarkers of treatment response, inhibition of metastasis and treatment resistance.

Metastasis, Progression and BiomarkersThe mechanisms responsible for prostate cancer cell dormancy, growth and metastasis will be explored in this session. Themes include immune surveillance, promoters of migration and invasion and the role of androgen receptor. The session will also explore new biomarkers for diagnosing, assessing, and monitoring the treatment response of prostate cancer, and how these biomarkers could inuence clinical outcomes.

Therapeutic Targets The ability of prostate cancer cells to survive, proliferate, migrate and invade provides targets for future therapies. This session explores a number of potential targets for therapeutic intervention.

Prostate Cancer Genetics and EpigeneticsThis session presents a number of genetic risk factors associated with prostate cancer, and an in-depth analysis of the genomic and epigenetic changes associated with prostate cancer progression, recurrence and metastases.

Co-ConvenorDr David SandallChief Operating Ofcer, Epworth Prostate Centre, Melbourne Australia

David brings experience in managing both academic research programs and R&D projects in the pharmaceutical industry

Co-ConvenorProf John MillsIs an internationally-recognized physician-scientist with several research interests including prostate cancer.

He is the Director of Research & Development at TissuPath Specialist Pathology, among other appointments, and he was Chair of the Prostate Cancer Foundation of Australia (PCFA) Research Program from 2007 to 2013

The translational science meeting brings together leading prostate cancer researchers, linking research from basic, translational and clinical researchers to improve outcomes for patients. Sessions will be themed-based and cover the following areas:

Convenors

Dr Geoff Coughlin

Dr Daniel Moon

Associate ProfessorDeclan Murphy

Masterclasses

This event has attracted large numbers of delegates in recent years to hear from world experts in robotic-assisted surgery and has proved one of the most highly-rated parts of the Program. The rapid growth in installation and procedure numbers since 2011 has led to a doubling in the number of systems available and a huge increase in the number of urologists transitioning to robotic-assisted surgery. This Masterclass remains the premium event for surgeons at all levels to hear from the best in the world and to improve their techniques.

This year we have assembled a hugely-experienced faculty of robotic surgeons to deliver an outstanding program for those interested in robotic-assisted radical prostatectomy using the da Vinci© surgical system. Dr Henk Van Der Poel (NKI, Amsterdam), Dr John Davis (MD Anderson, Texas) and Dr Markus Graefen (Martini Clinic, Hamburg) are world-leading experts in robotic cancer surgery and will lead the faculty in an all-day Masterclass focusing this year on more advanced aspects of the procedure. Urologists of all levels from trainee to experienced robotic surgeon will benet from this interactive and video-based da Vinci Prostatectomy Masterclass.

Highlights include:Ÿ Full-length da Vinci© radical prostatectomy and extended PLND (Henk Van Der Poel),

including uorescence-guided sentinel node dissectionŸ Creating Spaces – technical tips for difcult situations (John Davis)Ÿ Urethral dissection, apex preparation & frozen section biopsy – tips for maximizing

functional outcomes (Markus Graefen)Ÿ Video-based tutorials of difcult casesŸ Full schedule to be conrmed

In addition, a da Vinci© Si with simulator will be available all day in the trade area.

MASTERCLASS c


Pa

ge 2

9

Program8:30 – 10:30 SESSION 1 Chairs: Geoff Coughlin and Daniel Moon Unedited case - High risk prostate cancer | Henk van der poel Evidence for RARP – key robotic surgery publications from 2013-14 | Simon van Rij

10:30 – 11:00 Morning tea

11:00 – 12:30 SESSION 2 - Maximising Functional Outcomes Chairs: Peter Sutherland and Justin Peters11:00 – 11:20 Bladder neck preservation | Markus Graefen11:20 – 12:10 Nerve-sparing in 2014 – how I do it | Henk van der poel, John Davis, Geoff Coughlin12:10 – 12:30 Managing urethra/apex | Markus Graefen

12:30 – 13:30 Lunch

13:30 – 15:00 SESSION 3 - Tips and Tricks “Creating spaces” Chairs: John Yaxley and Laurence Harewood John Davis

15:00 – 15:30 Afternoon tea

15:30 – 17:00 SESSION 4 - High risk prostate cancer Chairs: David Bouchier-Hayes and Nathan Lawrentschuk15:30 – 16:00 Extended pelvic lymphadenectomy | John Davis16:00 – 16:20 Sentinel nodes | Henk van der Poel16:20 – 16:50 Salvage RARP post HIFU/focal therapy - UCL Experience | Paul Cathcart16:50 – 17:00 Discussion

Pa

ge 3

0

The use of MRI scanning for the diagnosis and staging of prostate cancer has become an area of considerable interest. The increased availability of 3T magnets and appropriate expertise has led to increased use of this modality. Improved image quality has also led to the use of multiparametric MRI images as part of a fusion-guided ultrasound approach to prostate biopsy.

To improve our knowledge in this area, we are presenting a Prostate MRI Imaging & Biopsy Masterclass led by Professor Jelle Barentsz, Professor and Head of Prostate Imaging at the Rabdoud University Medical Centre in the Netherlands. Professor Barentsz is the world's leading authority on prostate imaging using multiparametric MRI and has been a pioneer in the use of standardized reporting methodology (PIRADS) and also in the use of image-guided biopsy.

MASTERCLASS


Co-ChairA/Prof Stefan HeinzeDeputy Director of Radiology, Royal Melbourne HospitalStefan learnt prostate MRI with professor Hedvig Hricak at Memorial Sloan Kettering Cancer Center as part of a Body Imaging Fellowship.

He established the prostate MRI service at the Royal Melbourne Hospital and is involved in teaching prostate imaging. He is published in peer-reviewed journals and has presented widely at local and national meetings on prostate imaging.

Co-ChairDr Peter Swindle MBBS MS FRACSDr Peter Swindle is a urologist who specialises solely in prostate cancer. His expertise lies in robotic prostatectomy and he has a special interest in MRI of the prostate.

Dr Swindle trained in Queensland and subsequently completed a Masters of Surgery at the University of Sydney on magnetic resonance of the prostate. He then undertook a 2 year subspecialty Fellowship at Memorial Sloan-Kettering Cancer Centre in New York focusing on prostate cancer and undertook 2 years research on MRI of the prostate. He also completed an American Brachytherapy Fellowship at the Seattle Prostate Institute.

He has a research appointment at the Mater Medical Research Institute as well as clinical appointments at the Mater Private Hospital, Mater Adults Hospital, Greenslopes Private Hospital and the Wesley Hospital.


15th

Program10:00 – 10:05 Welcome / Course overview | Declan Murphy, Stephan Heinze

10:05 – 10:35 Lecture | Jelle Barentez

10:35 – 11:00 CADSTREAM orientation & How I report a prostate MRI | Stephan Heinze

11:00 – 11:30 Workstation based case review | Self-review

11:30 – 11:45 Case review with faculty | All faculty


12:30 – 12:45 Case review with faculty | All faculty

12:45 – 13:30 Lunch

13:30 – 14:00 Lectures | Peter Swindle


15:00 – 15:15 Afternoon Tea

15:15 – 15:30 Problem cases review with faculty | All faculty

15:30 – 16:00 Lecture and Closing comments | Jelle Barentez, Stephan Heinze

Faculty

A/Prof Juanita Crook

A/Prof Jeremy Millar

A/Prof Nathan Lawrentschuk

Dr David Clouston

Dr James MacKean

Dr John Yaxley

A/Prof Scott Williams

A/Prof Annette Haworth

The aim of this masterclass is to bring together experts in the eld of brachytherapy, focal therapy, imaging and pathology to present the evidence for developing a focal brachytherapy program. The workshop will include discussions on focal therapy alone for early low risk prostate cancer, focal boosts in whole gland monotherapy and salvage of focal recurrences.

Workshop aimsŸ To introduce the concept of focal distribution of cancer in the

prostate, Ÿ To review the evidence for imaging modalities to identify signicant

focal lesions,Ÿ To explore the role of brachytherapy in delivering focal therapy.

Who should attendAll those having an interest in the management of prostate cancer:Ÿ Radiation oncologistsŸ UrologistsŸ RadiologistsŸ PhysicistsŸ Radiation therapists

MASTERCLASS

Focal therapy: the role of LDR &HDR brachytherapy

Program10:30 – 11:10 The evidence for focal therapy A/Prof Juanita Crook, University of British Columbia, BCCA Center for the Southern Interior

11:10 – 11:30 Pathology and natural history of prostate cancer Dr David Clouston, Anatomical Pathologist, TissuPath

11:30 – 12:30 MRI for focal brachytherapy Dr James MacKean, Radiation Oncologist, & Dr John Yaxley, Urologist, Genesis Cancer Care, The Wesley Hospital, Brisbane

12:30 – 13:30 Lunch

13:30 – 14:00 Co-registration of imaging studies, the pros and cons of rigid vs. deformable registration A/Prof J Crook

14:00 – 14:20 Is there a gap in health care in Australia that focal brachytherapy can ll? A/Prof Jeremy Millar, Director, Radiation Oncology, WBRC & WBRG, Alfred Health

14:20 – 15:00 Treatment options for focal therapy A/Prof Nathan Lawrentschuk, U. Melbourne, Dept of Surgery and Ludwig Institute for Cancer Research, Austin Hospital and Peter MacCallum Cancer Centre

15:00 – 15:30 Afternoon tea

15:30 – 16:00 Treatment response following focal therapy, when do we know we have succeeded? A/Prof Scott Williams, Radiation Oncology, Peter MacCallum Cancer Centre, U. Melbourne

16:00 – 17:00 Are we ready for a focal brachytherapy trial in the Asia-Pacic Region? Proposer: Dr Ana Fernandez-Ots Discussant: A/Prof Juanita Crook Panel discussion: A/Prof Juanita Crook, A/Prof Jeremy Millar, A/Prof Nathan Lawrentschuk, Dr David Clouston, Dr James MacKean, Dr John Yaxley, A/Prof Scott Williams, A/Prof Annette Haworth

Pa

ge 3

1

Pa

ge 3

2

Social Program

Welcome Reception and Poster View Session

Date: Sunday 31 August, 2014

Time: 5.00pm – 7.00pm

Venue: Melbourne Convention

Centre, Ground Floor

Cocktail drinks and canapés will be served in the Exhibition Space on ground level.

Delegates are welcome to roam the exhibition and see the latest research in all areas of Prostate Cancer. Talk one on one with presenters about their work.

Prizes will be awarded in each of the following categories:

Ÿ Clinical Urology

Ÿ Translational Science

Ÿ Nursing & Allied Health

Conference Dinner

Date: Monday 1 September, 2014

Time: 7:00pm – 11:30pm

Venue: Mural Hall, Myer

Dress: Lounge Suit

Take one step inside Mural Hall and you will be transported to another world. Perhaps it is the Parisian inspiration, the parquet ooring or the 18th century style mirrored commodes that dance light around the room, that create the illusion that you are celebrating in a lavish European ballroom. Or perhaps it's because you are.

Getting There:Coach transfers will depart from the Melbourne Convention Centre (South Wharf Entrance) following the Janssen Satellite Symposium


15th

Directions:Ÿ Enter via Postal Lane off

Little Bourke StreetŸ A Mural Hall Staff member

will be at the entrance with a sign to direct you

Ÿ Take the lifts to Level 6

Enter via

Postal Lane >

Registration Information

Consultant/Trainee/ Registrar/Fellow Full Registration includes:Ÿ Entry to all conference

sessions (Sunday Tuesday)

Ÿ Morning and Afternoon Teas and Lunch Daily

Ÿ Attendance to either the da Vinci Masterclass or LDR Brachytherapy Masterclass (Sunday 31 August)

Ÿ Attendance at the Welcome Reception & Poster Viewing (Sunday 31 August)

Ÿ Entry into the Exhibition Area

Ÿ Delegate SatchelŸ Final Program

Nursing & Allied Health Full Registration includes:Ÿ Entry to all conference

sessions (Sunday Monday)



Ÿ Entry into the Exhibition Area (Sunday Monday)

Ÿ Delegate SatchelŸ Final ProgramŸ Option to purchase a

conference upgrade to include Tuesday Conference attendance for an additional $100.00

Masterclass Only Registration includes:Ÿ Entry to nominated

MasterclassŸ Morning and Afternoon

Teas and Lunch on Sunday 31 August

Ÿ Entry into the Exhibition Area on Sunday 31 August

Ÿ Delegate SatchelŸ Final ProgramŸ Attendance at the

Welcome Reception & Poster Viewing

Registration Desk HoursThe Registration Desk will be open during the following hours:

Sunday 31 August07:00 - 17:30

Monday 1 September07:00 - 17:30

Tuesday 2 September06:45 - 16:00

Scientist/Researcher/ Student/Post Doc Full Registration includes:Ÿ Entry to all conference

sessions (Monday Tuesday)



Ÿ Entry into the Exhibition Area (Monday Tuesday)

Ÿ Delegate SatchelŸ Final Program

Day Registration includes:Ÿ Entry to all conference

sessions on day of Registration

Ÿ Morning and Afternoon Teas and Lunch on day of Registration

Ÿ Entry into the Exhibition Area on day of Registration

Ÿ Delegate SatchelŸ Final ProgramŸ Attendance at the

Welcome Reception & Poster Viewing (Nursing & Allied Health Sunday Tickets Only)

Pa

ge 3

3

Pa

ge 3

4

Presentation InformationChairs and Session ModeratorsPlease ensure that you are available in your presentation room at least ten minutes prior to the start of the session.

Oral PresentationsIt is important that all speakers upload their presentation in the Speakers' Preparation Room at least two hours prior to the commencement of their allocated session. Speakers who are presenting at an early morning session should check-in their presentation the day before their presentation. An audio visual technician will be available in the Speakers' Preparation Room to assist with this process.

Poster PresentationsPosters will be displayed from Sunday 31 August through to the conclusion of the Conference on Tuesday 2 September. Poster presenters must check-in at the Registration Desk prior to setting up their posters in the Trade area. The presenting author must be present at their poster during the Poster Session from 17:00 - 19:00 on Sunday 31 August.

Speakers' Preparation RoomThe Speakers' Preparation room is adjacent to the Registration Desk in the foyer of the Melbourne Convention Centre and will be open during the following hours:

Sunday 31 August 0700 – 1730

Monday 1 September 0700 – 1730

Tuesday 2 September 0700 – 1530

Speakers are requested to load their presentation with the AV Technicians at the Speaker's Preparation room a minimum 2 hours prior to their scheduled presentation.

Yar

Melbourne Convention

and Exhibition Centre

LA TROBE ST

WILLIA

M S

T

KIN

G

KIN

G S

TSPEN

CER STREET

CLAREN

DO

N

LITTLE LONSDALE ST

LONSDALE ST

LITTLE BOURKE ST

BOURKE ST

LITTLE COLLINS ST

COLLINS ST

FLINDERS LANE

WHIT

EMAN S

TREET

Crown

Entertainment

Complex

SOUTHERN CROSS

STATION

Yarra

P

romenade

1

2

4

Melbourne Convention and Exhibition Centre

MelbourneYour Host City

Pa

ge 3

5

Accommodation

Hilton MelbourneSouth Wharf (Conference Hotel)2 Convention Centre Place, South Wharf

Crown MetropolMelbourneCnr Clarendon Street and Whiteman Streets, Southbank

Crown PromenadeMelbourneCnr Queensbridge and Whiteman Streets, Southbank

Travelodge Docklands66 Aurora Lane, Docklands

Oaks on Market60 Market Street,Melbourne

EXH

IBITIO

N S

T

RUS

SELL S

T

FLINDERS ST

Princes Walk

Federation

Square

Yarra River

Yarra River

RUS

SELL S

T

SW

AN

STO

N S

TREET WA

LK

FLINDERS ST

ELIZAB

ETH S

T

QU

EEN S

TWILLIA

M S

T

HA

RDW

ARE

BOURKE ST MALL

CITY R

OAD

WHIT

EMAN S

TREET

QU

EEN

S B

RID

GE

POWER ROAD

SOUTHBANK

BOULEVARD

GPO

Crown

Entertainment

Complex

FLINDERS STREET

STATION

Enterprize Park

Southbank Promenade

Yarra

P

romenade

Banana Alley

Flinders Walk

Princes Walk

Federation

Square

3

Mural HallMyer Building Conference Dinner

5

MA

RKET S

T

1

2

3

4

5

Pa

ge 3

6

General Information

Attendance CerticateA certicate of attendance is available upon request post conference. Please see the staff at the registration desk or contact [email protected]

Car ParkingParking is available at the Melbourne Exhibition Centre and adjacent car parks.

CateringAll morning teas, lunches and afternoon teas during the conference are included in your registration fee and will be served in the Exhibition.

A separate buffet will be setup in the Exhibition to cater for delegates who require a special dietary meal.

Conference OfceICMS Pty LtdPO Box 170 Hawthorn VIC 3122P: 1300 792 466F: +61 3 9818 7111E: [email protected]

Name BadgesYour name badge is your entrance ticket to all Conference sessions and the Exhibition. Please wear your name badge at all times.

No Smoking PolicyDelegates should be aware that smoking is banned in public buildings and hotels and restaurants throughout Victoria, including the Conference venue.

TicketsYour tickets for the masterclasses, breakfasts and Conference dinner are included in your name badge holder. If you have misplaced your tickets or have not received tickets for functions you wish to attend, please see the staff at the Registration Desk.

WIFIWIFI access is available free of charge throughout the Exhibition and in the Business Centre. Visit the APCR Business Centre in the Trade Area to use the computers.

Liability DisclaimerIn the event of industrial disruption or other unforeseen circumstances, the Conference Ofce, the Organising Committee and the Host Organisations accept no responsibility for loss of monies incurred by participants and /or accompanying persons. The Conference Ofce, the Conference Committee and the Host Organisations accept no liability for injuries/losses of whatever nature incurred by participants and/or accompanying person, nor for loss or damage to their luggage and/or personal belongings. Participants and or/accompanying persons should make their own arrangements with respect to personal insurance.

Mobile Phones and Pagers As a courtesy to speakers and other delegates, we request that all mobile phones and pagers are in silent mode or switched off before entering sessions.

MessagesThe Conference registration desk staff will take messages for delegates during the Conference. Messages will be posted on the message board, located next to the registration desk. Delegates are requested to check the message board during breaks.


15th

Pa

ge 3

7

Exhibition Information

The Exhibition is located in Main Foyer of the Melbourne Convention Centre and will be open during the following hours:

Sunday 31 August 1000 – 1900

Monday 1 September 0900 – 1700

Tuesday 2 September 0900 – 1530

Exhibitors

Abbvie Pty Ltd 28

Amgen 8

AMS Australia 10

Astellas 19 & 20

AstraZeneca 27

Australian Prostate Cancer Research Business Centre

Bayer 6 & 7

Coloplast 17

Device Technologies 26

Ferring Pharmaceuticals 25

Imaging Solutions 11

Innologic 16

IPSEN Pty Ltd 4 & 5

Janssen 29

Karl Storz Endoscopy 22

Meditron Pty Limited 9

N. Stenning & Co. 12

Neotract Australia Pty Ltd 18

Olympus Australia 2 & 3

Prostate Cancer Foundation of Australia 14

Sano 1

Scanmedics 23

Société Internationale d’Urologie (SIU) 21

Tolmar Australia 24

H

H

H

H

UP

UP

Co

ffe

eS

tatio

n

EN

TR

Y

EN

TR

Y/E

XIT

EX

IT

BusinessCentre

19

20

21

22

23

18

16

17

91

011

24

26

12

14

12

34

5

29

27

82

8C

ate

rin

gS

tatio

n

Ca

teri

ng

Sta

tio

n

Ca

teri

ng

Sta

tio

n

RE

GIS

TR

AT

ION

PO

ST

ER

DIS

PLAY

S

25

Exhibition Information

Pa

ge 3

8

continued

Pa

ge 3

9

Exhibitor Profiles

STAND 28

Abbvie Pty Ltd Contact Tessa James

Address 32-34 Lord Street Botany

NSW 2019 Australia

Telephone +61 2 9035 8600

Facsimile +61 2 9035 8601

Email [email protected]

Website www.abbvie.com.au

AbbVie is a new & different kind of company that combines focus & passion of a leading biotech with expertise & structure of a long established pharmaceutical leader.

We’d like to tell you more about the creative & innovative ways AbbVie is helping support clinicians & their patients. Visit us at the AbbVie stand and www.abbvie.com

STAND 10

AMS AustraliaContact Pat Callanan

Address Unit 31 F, 16 Mars Road Cove West

NSW 2066 Australia

Telephone +61 2 9425 6800

Facsimile +61 2 9427 6296


Website www.americanmedicalsystems.com

AMS is the world’s leading company focused on developing, manufacturing and marketing medical devices that restore male and female pelvic health. AMS Australia utilises this global strength to provide quality solutions and unmatched resources to Urologists throughout Australia and New Zealand covering prosthetic urology, BPH solutions and female urology. Our training initiatives, in surgery support, staff knowledge and staff dedication sees us providing a true partnership in numerous practices throughout Australia and New Zealand for the long term.

STAND 8

AmgenContact Anne Sullivan

Address Level 7, 123 Epping Road

North Ryde NSW 2113 Australia

Telephone +61 2 9870 1333

Facsimile +61 2 9870 1344


Website www.amgen.com.au

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

STAND 19 & 20

Astellas Pharma Australia Pty Ltd

Contact Michelle Commane

Address Suite 4, Level 4, 6 Eden Park Drive,

Macquarie Park. NSW 2113 Australia

Telephone + 61 2 9814 1100

Facsimile + 61 2 9814 1120

Website www.astellas.com.au

Business Centre

Australian Prostate Cancer ResearchContact James Garland

Address Locked Bag 10, East Melbourne,

8002, VICTORIA

Telephone +61 3 9421 0985


Website www.prostatecancerresearch.org.au

Australian Prostate Cancer Research is a national research organisation that partners with leading institutions to develop, fund and deliver national research programs. We are committed and driven to discover new tests, new treatments and to educate the industry on all aspects of diagnosis, treatment and patient care.

STAND 17

ColoplastContact Desi Mavros

Address 33 Gilby Road Mt Waverley

VIC 3149 Australia

Telephone 0403 551 239

Facsimile +61 3 9541 1199


Website www.coloplast.com.au

Coloplast Porges is a leading global manufacturer and marketer of innovative medical devices for the management

and treatment of urological conditions to include incontinence, pelvic organ prolapse, Peyronie’s Disease and ED. Products include: Titan®/Genesis® penile prostheses, Virtue® male sling, Torosa®/KiWeeTM testicular prostheses, Restorelle® mesh, Aris®/Supris™/Altis™ sling systems, BoNee® bladder injection needles.

Pa

ge 4

0

STAND 27

AstraZeneca AustraliaContact Simone Holst

Address 5 Alma Road North Ryde

NSW 2113 Australia

Telephone +61 2 9978 3500

Facsimile +61 2 9978 3700

Website www.astrazeneca.com.au

AstraZeneca Australia, based in North Ryde, Sydney, is the largest pharmaceutical company operating in Australia. AstraZeneca employ almost 1,000 people, are one of the country’s largest manufacturers of medicines and are a key exporter to 35 international markets. AstraZeneca manufactures 100 separate product lines, namely sterile respiratory and local anaesthetic products. Of the top twenty medicines used in Australia, four are made by AstraZeneca. AstraZeneca produces medicines in six separate therapeutic areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience and respiratory inammation. AstraZeneca contributes signicantly to clinical trials in Australia with approximately 30 concurrent trials in 190 sites across the country.


15th

STAND 25

Ferring PharmaceuticalsContact Gretchen Pryba

Address PO Box 135 Pymble

NSW 2073 Australia

Telephone 1800 33 77 46

Facsimile +61 2 9497 2399


Website www.ferring.com.au

Ferring Pharmaceuticals is a Swiss-based research-oriented pharmaceutical company that specialises in products in the eld of Urology/Oncology, Gastroenterology, Endocrinology and Reproductive Health. At this meeting, Ferring Pharmaceuticals is featuring FIRMAGON® (degarelix), a GnRH receptor antagonist. Visit us at the Ferring stand to learn about FIRMAGON® and its reconstitution and administration process.

STAND 11

Imaging SolutionsContact Renee Campbell

Address PO BOX 1768 Sunnybank Hills

QLD 4109

Telephone +61 7 3209 9712

Facsimile +61 7 3209 9812


Website www.imagingsol.com.au

Imaging Solutions is a healthcare imaging equipment products and consumables supplier. Our critical point of difference is our "single source supplier" philosophy which allows us to offer unmatched convenience and value for money to all our customers. Imaging Solutions offers an extensive range of world-market-leading, rst quality, high performance products which assist our customers in delivering outstanding radiographic diagnostic quality rst time, every time.

STAND 26

Device TechnologiesContact Marta Orczykowska

Address 1 Garigal Road Belrose

NSW 2085 Australia


Facsimile 1800 999 323


Website www.device.com.au

Founded in 1992, Device Technologies is an established distributor of quality and technologically-advanced medical equipment and consumables. The company is Australian-owned and employs more than 500 healthcare specialists and support staff in Australia and New Zealand.

Ÿ All products are professionally supported by qualied Product Managers and specialists, trained to work in surgical and operating room environments.

Ÿ Clinical Educators provide accredited training, in-servicing and ongoing clinical support.

Ÿ Technical Service personnel service and maintain our extensive range of capital equipment.

Ÿ Regulatory Affairs ensure all products are correctly listed with the TGA.

Company Mission Statement:To enable superior health outcomes for patients, by providing access to the best medical systems available worldwide

Pa

ge 4

1

STAND 29

Janssen Contact Jacqui Wade

Address 66 Waterloo Road Macquarie Park

NSW 2113 Australia

Telephone +61 2 9815 3380

Facsimile +61 2 9475 0316


Website www.janssen.com.au

Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology (e.g. multiple myeloma, Prostate, Ovarian and Breast cancer), immunology (e.g. psoriasis), neuroscience (e.g. schizophrenia, dementia and pain), infectious disease (e.g. HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g. diabetes).

STAND 22

Karl Storz EndoscopyContact Amanda Silverstone

Address Annex Building, 15 Orion Road

Lane Cove West NSW 2066 Australia

Telephone +61 2 9490 6700

Facsimile +61 2 9420 0695


Website www.karlstorz.com

KARL STORZ has established itself worldwide as an international and highly regarded company in the production and sale of endoscopic devices, documentation and cameras. The majority of manufacturing is carried out in Tuttlingen, Germany where the art of instrument making is alive and well.

We will be showcasing the newest products to the market, including CMOS Video Cystoscope, 7Fr semi rigid ureteroscope, Green Light Laser Telescope and High Flow Sheath and UROMAT EASI, the newest Fluid Management System on the market.

STAND 16

InnologicContact Dale Johnston

Address 6 Gould Street, Herdsman Business

Park, Osborne Park WA 6017


Facsimile +61 2 8583 3333


Website www.innologic.com.au

Innologic’s focus is innovation in healthcare combined with exceptional customer service.

Each device in our range was selected for its quality, reliability, & ability to support the needs of busy clinics. We are focused on being the preferred supplier of equipment, technical service & associated clinical support for our customers.

STAND 4 & 5

IPSEN Pty LtdContact Kelly Gillin

Address Level 2, Building 4, Brandon Ofce

Park, 540 Springvale Road

Glen Waverley VIC 3150 Australia

Telephone +61 3 8544 8100

Facsimile +61 3 9562 5152


Website www.ipsen.com.au

Ipsen provides specialty medicines and quality services to Healthcare Professional and their patients suffering from debilitating diseases.

At Ipsen, our passion is improving the lives of patients. We do this by working together to build partnerships based on trust and mutual respect with Healthcare Professionals. We deliver tailored solutions through our agility and innovation and we strive to be even better tomorrow than we are today.

Ipsen Pty Ltd is the Australian afliate of a global R & D focused pharmaceutical company.

Pa

ge 4

2


15th

STAND 18

Neotract Australia Pty LtdContact Tracee Stannard

Address Unit 13 76 Reserve Road Artarmon

NSW 2064 Australia

Telephone +61 2 9436 0487

Facsimile +61 2 9475 4558


Website www.neotract.com

NeoTract, Inc. is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift® System, a minimally invasive permanent device designed to treat LUTS. Learn more at www.UroLift.com.

STAND 2 & 3

Olympus AustraliaContact Jada Tomas

Address 3 Acacia Place, Notting Hill VIC 3168

Telephone +61 3 9271 5513

Facsimile +61 3 9562 6416


Website www.olympusaustralia.com.au

Olympus is an innovative technology and service provider, excelling in the eld of Urology. With the complete product portfolio in Urology offering unique video scopes and bipolar PlasmaButton Vaporisation in addition to our range of Endourology consumable products, we are the company to partner with for your daily diagnostic and therapeutic requirements.

STAND 9

Meditron Pty LimitedContact Michael Fehrmann

Address PO Box 4230 Ringwood

VIC 3134 Australia

Telephone +61 3 9879 6200

Facsimile +61 39879 6244


Website www.meditron.com.au

Meditron supply the complete range of Dornier MedTech products. These include Lithotripters, Urotables, Holmium Stone Laser and the UroBeam laser for BPH.

Meditron also offers technology for MRI-Fusion and intelligent Perineal Prostate Biopsies.

Furthermore, Meditron distribute CIVCO transducer covers and needle guides for TRUS-procedures.

STAND 12

N. Stenning & Co.Contact Derek Foltin

Address 174 Parramatta Road Camperdown

NSW 2050 Australia

Telephone +61 2 8594 9100

Facsimile +61 2 8594 9188


Website www.nstenning.com.au

N. Stenning & Co. has been proudly selling innovative equipment for over 60 years in the medical devices industry. Featured will be our Hem-o-lok ligating clip system, Storz Medical ESWT and ESWL, and other medical devices specically for prostate surgery.

Pa

ge 4

3

STAND 23

Scanmedics

Contact Paul Blewitt

Address Unit 6 15-17 Gibbes Street

Chatswood NSW 2067 Australia

Telephone +61 2 9882 2088

Facsimile +61 2 9882 3549


Website www.scanmedics.com

Scanmedics has been the provider of BK Medical ultrasound solutions for over 18 years in Australia and New Zealand. Founded in 1996 by MaryAnne Taylor and David Gibson, the Scanmedics team has attained a reputation for working with clinicians to support patient centred care while improving their clinical outcomes. BK Medical’s superior image quality with Quantum+ technology makes a diagnostic difference to prostate imaging.

STAND 14

Prostate Cancer Foundation of Australia Contact Marieke Koets

Address Level 3, 39 Chandos Street

St Leonards NSW 2065

Telephone +61 2 9438 7095

Facsimile +61 2 9438 7099


Website www.prostate.org.au

Prostate Cancer Foundation of Australia (PCFA) is a broad-based community organisation and the peak national body for prostate cancer in Australia. We are dedicated to reducing the impact of prostate cancer on Australian men, their partners, families and the wider community.

We do this by:Ÿ Promoting and funding world leading,

innovative research into prostate cancerŸ Implementing awareness campaigns and

education programs for the Australian Community, health professionals and Government

Ÿ Supporting men and their families affected by prostate cancer through evidence-based information and resources, support groups and Prostate Cancer Specialist Nurses

PCFA receives Government funding for specic projects and relies on the generosity of individuals, the community and partnerships, such as those with the Movember Foundation and Commonwealth Bank, to carry out our essential work.

STAND 1

Sano

Contact

Address Talavera Corporate Centre 12 – 24

Talavera Road Macquarie Park

NSW 2133 Australia

Telephone +61 2 8666 2000

Facsimile +61 2 8666 3000

Website www.sano.com.au

The ambition of Sano is to become a diversied global healthcare leader, focused on patients’ needs, the largest pharmaceutical company in Europe and in emerging markets, Sano is the fourth largest worldwide. The Group’s vaccine division, Sano Pasteur, is the world leader for human vaccine production and commercialisation.

Pa

ge 4

4


15th

STAND 21

Société Internationale d’Urologie (SIU)

Address 1155 University Street, Suite 1012

Montreal, QC H3B 3A7 Canada

Telephone +1 514 875 5665

Facsimile +1 514 875 0205


Website www.siu-urology.org

The Société Internationale d’Urologie (SIU) prides itself on fullling the educational needs of its members, and on mobilizing technology to reach the greatest numbers of urologists worldwide. In October 2014, the SIU launched its virtual platform enabling the SIU Congress to go hybrid. Visit Booth # 21 to learn more about our 35th congress in Melbourne, Australia, Oct. 15 – 18, 2015. Visit us at: www.siu-urology.org for more information on the different facets of the SIU.

STAND 24

Tolmar Australia

Contact Michael Sapurmas

Address Building 2 Level 2 Suite 4,

20 Bridge St Pymble NSW 2073

Telephone +61 2 9440 6700

Facsimile +61 2 9440 6750


Website www.tolmar.com.au

New uro-oncology player Tolmar Australia is well resourced and motivated to support real improvements in the quality of life for men with prostate cancer. The company sponsors an innovative in-home injection service, Eligard® NurseCARE (independently run by AESIR Health), that aims to ease the treatment experience. TOLMAR is actively looking to fund researchers to encourage further advancements. With a collaborative mindset, Tolmar Australia is also a proud sponsor of the Prostate Cancer Foundation of Australia.

Pa

ge 4

5

Join the conversation on Twitter! Follow @AustProstate

and #apcc14 for latest updates

Australian

Prostate Cancer

Research


15th

www.prostatecancerconference.org.au

Follow us on twitter #apcc14@AustProstate

CLINICAL UROLOGY | TRANSLATIONAL SCIENCE | NURSING & … · 2019. 6. 24. · Clinical Urology 20-21...

Documents

Transcript of CLINICAL UROLOGY | TRANSLATIONAL SCIENCE | NURSING & … · 2019. 6. 24. · Clinical Urology 20-21...